Robert C. Meisner

2 papers in the library · 6 citations · publishing 2025

Papers

Comparative Effects of Repeated Ketamine Infusion Versus Intranasal Esketamine in Patients With Treatment-Resistant Depression: A Retrospective Chart Review.

Journal of Clinical Psychiatry September 22, 2025 Robert C. Meisner, Shuang Li, Brian W. Boyle et al. 5 citations

In patients with severe treatment-resistant depression, intravenous racemic ketamine produced a faster and larger reduction in depressive symptoms than intranasal esketamine. Over eight treatment sessions, those receiving IV ketamine showed a 49.22% decrease in depression scores, compared to a 39.55% decrease with intranasal esketamine. The IV group showed significant improvement after just one treatment, while the intranasal group required two treatments. Both treatments were effective, but IV ketamine was associated with greater overall efficacy and more rapid response.

DOI: 10.4088/jcp.25m15789 Medicine

Ketamine improves anhedonic phenotypes across species: Translational evidence from the Probabilistic Reward Task

medRxiv Preprint Server June 2, 2025 Mario Bogdanov, Jason N. Scott, Shiba M. Esfand et al. 1 citation preprint

A single, subanesthetic dose of ketamine improved reward responsiveness in both humans with treatment-resistant depression and chronically-stressed rats, measured using functionally identical tasks. The finding suggests that ketamine's rapid antidepressant effects may involve enhancing reward processing, a core feature of anhedonia. The work provides translational evidence linking preclinical and clinical observations, though the mechanisms remain unclear.

DOI: 10.1101/2025.06.02.25328447 Full text Treatment-resistant depression Ketamine treatment Ketamine therapy Severe depression +12